Company Overview and News
Andromeda Metals Ltd (ASX:AND) has signed a deal with Minotaur Exploration (ASX:MEP) to form a joint venture over its fully-owned Rover Copper-Gold Project tenements in the Northern Territory.
Andromeda Metals and Minotaur Exploration have announced they will form a joint venture for $5 million in exploration funding at Andromeda’s 100 per cent-owned Rover copper-gold project in Tennant Creek, Northern Territory.
OZ Minerals and Minotaur Exploration have mutually decided to end an exploration collaboration in the Prominent Hill area of South Australia.
Minotaur Exploration Ltd (ASX:MEP) has a portfolio of exploration projects in Australia, including an alliance with Oz Minerals (ASX:OZL) in South Australia, near the Prominent Hill copper-gold mine.
Alt Resources Ltd (ASX:ARS) has entered an agreement to acquire the Chameleon gold deposit and associated tenements in the Eastern Goldfields of Western Australia. Chameleon has a JORC 2012 resource of 1.1 million tonnes grading 2.1 g/t gold for 77,000 ounces of gold. The Chameleon deposit has substantial exploration upside, including numerous drill-ready targets. James Anderson, CEO, commented: “Chameleon is an undeveloped asset with oxide open pit potential and exploration upside.
Minotaur Exploration Ltd (ASX:MEP) has been granted a trading halt by the ASX, with its shares placed in pre-open. Minotaur requested the halt to enable the company to review the drilling data and to prepare a suitable release to the market. The halt will remain in place until the opening of trade on Tuesday 27th September 2016, or earlier if an announcement is made to the market.
Minotaur Exploration Ltd (ASX:MEP) has exploration tenements in South Australia, New South Wales, Victoria, Queensland and the Northern Territory.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...